User:Mr. Ibrahem/Vemurafenib

Mr. Ibrahem/Vemurafenib
Clinical data
Pronunciation	/ˌvɛməˈræfənɪb/ VEM-ə-RAF-ə-nib
Trade names	Zelboraf
Other names	PLX4032, RG7204, RO5185426
AHFS/Drugs.com	Monograph
MedlinePlus	a612009
License data	EU EMA: by INN; US FDA: Vemurafenib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth (tablets)
Drug class	BRAF kinase inhibitor
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Identifiers
	IUPAC name N-(3-{[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide;
Chemical and physical data
Formula	C23H18ClF2N3O3S
Molar mass	489.92 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCS(=O)(=O)Nc1ccc(F)c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(Cl)cc4;
	InChI InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28) ; Key:GPXBXXGIAQBQNI-UHFFFAOYSA-N ;
	(verify)

Vemurafenib, sold under the brand name Zelboraf, is a medication used to treat certain types of late-stage melanoma and Erdheim-Chester disease.^[2] Specifically it is used in those with a BRAF V600E mutation.^[2] It is taken by mouth.^[2]

Common side effects include joint pain, hair loss, itchiness, QT prolongation, and tiredness.^[2] Other side effects may include Dupuytren contracture, sensitivity to radiation therapy, eye inflammation, liver problems, and a new cancer.^[2] Use in pregnancy may harm the baby.^[2] It works by blocking the b-Raf enzyme.^[2]

Vemurafenib was approved for medical use in the United States in 2011 and Europe in 2012.^[2]^[3] In the United Kingdom 56 tablets of 240 mg costs the NHS about £1,750 as of 2021.^[1] This amount in the United States costs about 2,650 USD.^[4]

References[edit]

^ ^a ^b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1062. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Vemurafenib Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 13 September 2021.
^ "Zelboraf". Archived from the original on 10 April 2021. Retrieved 13 September 2021.
^ "Zelboraf Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 29 August 2021. Retrieved 13 September 2021.

[BNF80-1] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1062. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Vemurafenib Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 13 September 2021.

[EPAR2021-3] "Zelboraf". Archived from the original on 10 April 2021. Retrieved 13 September 2021.

[4] "Zelboraf Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 29 August 2021. Retrieved 13 September 2021.

[1]

[2]

[3]

[4]